Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation.

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Transplantation Immunology

Background:

• Chronic kidney disease (CKD) is linked to a higher risk of cardiovascular events.
• Investigating inflammation and endothelial dysfunction markers is crucial in CKD patients undergoing transplantation.

Purpose of the Study:

• To examine the changes in inflammation and endothelial dysfunction markers before and after living donor kidney transplantation.
• To understand the association between Asymmetric dimethylarginine (ADMA) and flow-mediated dilation (FMD) in CKD patients.

Main Methods:

• Studied 27 renal transplant recipients (cyclosporine A or tacrolimus-based regimens) and 27 controls.
• Measured plasma adiponectin, high-sensitivity C-reactive protein (hsCRP), and ADMA levels pre-transplant and on days 1, 3, 7, 14, and 28 post-transplant.
• Assessed brachial artery flow-mediated dilation (FMD) pre-transplant and on day 28 post-transplant.

Main Results:

• Serum hsCRP and ADMA levels decreased significantly from day 1 post-transplant (P<0.001).
• Plasma adiponectin levels began to decrease by day 3 post-transplant (P<0.001).
• FMD was lower in patients than controls (P<0.001) but improved significantly by day 28 post-transplant (P<0.001).

Conclusions:

• ADMA is significantly associated with FMD in CKD patients, both pre- and post-kidney transplantation.
• Endothelial function shows early improvement post-transplant, coinciding with reductions in ADMA and hsCRP.
• Living donor kidney transplantation effectively mitigates markers of inflammation and improves endothelial function in CKD.